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Abstract
 
GD3, a ganglioside expressed on human melanoma, can be recognized by the humoral immune
system. In this paper, we demonstrate that immunizing mice with the human melanoma cell
line SK-MEL-28 (GD3
 
 
 
 GM2
 
 
 
 CD1
 
 
 
) or with syngeneic APCs loaded with GD3 can induce
a GD3-reactive natural killer T (NKT) cell response. GD3-reactive NKT cells were detected
among splenocytes of immunized mice at frequencies of 
 
 
 
1:2,000 both by ELISPOT and
GD3-loaded mouse CD1d tetramer analysis. GD3-reactive NKT cells did not react with GM2,
a closely related ganglioside, and were not detectable in unimmunized mice. GD3-reactive
NKT cells initially produced IL-4 and IFN-
 
 
 
 followed by IL-10. They were CD1d restricted
in that reactivity was abrogated when APCs were blocked with anti-CD1d monoclonal anti-
body before being loaded with GD3 or when APCs from CD1d knockout mice were used.
Because SK-MEL-28 does not express any isoform of human CD1, GD3 must be cross-pre-
sented by murine APCs in vivo. This is the first analysis of a natural ligand for mouse NKT
cells and the first definitive paper of cross-presentation to NKT cells. This could be a mecha-
nism for NKT cell recognition of tumor gangliosides in CD1
 
 
 
 tumors.
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Introduction
 
CD1 molecules are a family of antigen-presenting mole-
cules with the ability to present lipids and glycolipids to T
cells and to natural killer T (NKT)
 
*
 
 cells (1). Many of the
glycolipids presented by the CD1 family, such as bacterial
glycolipids (e.g., glucose monomycolate; reference 2),
 
 
 
-galactosylceramide (
 
 
 
GalCer) from marine sponges (3),
and self monosialogangliosides (GM1; reference 4), share a
structural motif comprising a hydrophilic head group and
two hydrophobic acyl chains (5). CD1d, the only CD1 iso-
form expressed in the mouse, has two hydrophilic pockets
likely to accommodate hydrophobic acyl tails of glycolipid
molecules, allowing the hydrophilic carbohydrate portion
to be presented to the TCR (6).
In mice, most NKT cells (NK1.1
 
 
 
 TCR
 
  
 
 
 
) are reac-
tive to glycolipids in the context of CD1d. They are phe-
notypically and functionally heterogeneous and may be
CD4
 
 
 
, or CD4
 
 
 
8
 
 
 
 double negative (DN; reference 7), al-
though they tend to express an invariant TCR 
 
 
 
-chain
formed by a V
 
 
 
14-J
 
 
 
18 rearrangement paired with a lim-
ited TCR 
 
 
 
 chain repertoire (8, 9). 
 
 
 
GalCer, a marine
sponge glycolipid not present in mammalian cells, has been
found to be a universal ligand for NKT cells expressing in-
variant V
 
 
 
14-J
 
 
 
18 TCR (3), and these NKT cells can be
identified using 
 
 
 
GalCer-CD1d tetramers (10, 11). Al-
though 
 
 
 
GalCer is the best-characterized antigen for
NKTs, no natural ligands of mouse NKT cells have been
identified to date.
GD3 is a relatively tumor-restricted ganglioside highly
expressed on human tumors of neuroectodermal origin
(e.g., melanoma [12] and small-cell lung carcinoma [13]),
but it is expressed on only a few normal tissues in the hu-
man or mouse, and at low levels. Although mAb against
GD3 can induce antimelanoma responses in animal models
and in humans (14–16), there is no information as to
whether GD3 can induce a cellular immune response. In-
deed, gangliosides have been reported to inhibit T cell re-
sponses (17), although some form of T cell help would be
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anticipated to explain the generation of anti-GD3 IgG in
immunized mice.
The structure of GD3 suggested the possibility that GD3
could be presented by members of the CD1 family. Indeed,
previous analyses showed that in the human system, T cells
reactive against a GM1 ganglioside could be detected (18).
We were interested to determine if GD3 can be presented
by CD1d to mouse NKT cells.
 
Materials and Methods
 
Mice. 
 
Female inbred C57BL/6 mice, 4–6-wk old, purchased
from the National Cancer Institute were used throughout this
work. CD1d knockout (CD1d
 
 
 
/
 
 
 
) mice were provided by Dr.
S.P. Balk (Harvard Medical School, Boston, MA). 2C mice, which
are transgenic for the TCR-recognizing peptide SIYRYYGL
(19), were provided by Dr. D. SantAngelo (Sloan-Kettering In-
stitute, New York, NY). Mice were maintained in our animal fa-
cility under specific pathogen-free conditions.
 
Immunization Protocol. 
 
Human melanoma cell line, SK-
MEL-28, which expresses GD3 but does not express GM2 (20),
was used for immunizing mice. For immunization, mice were in-
jected s.c. with 2 
 
 
 
 10
 
6
 
 SK-MEL-28 mixed with CFA (Sigma-
Aldrich) and boosted 1 wk later with 2 
 
 
 
 10
 
6
 
 SK-MEL-28 with
IFA (Sigma-Aldrich). In the control group, mice were injected
with CFA followed by IFA only without SK-MEL-28. Mice
were killed 1 wk after boost, and spleen, liver, and thymus were
removed and processed individually.
In some experiments, naive mice were injected s.c. into foot-
pads with 10
 
5
 
 syngeneic APCs loaded with 1 
 
 
 
g/ml GD3 or un-
loaded APCs. On day 7, splenocytes were collected and pro-
cessed individually, and popliteal and inguinal LN were collected
and pooled.
For experiments measuring the kinetics of cytokine produc-
tion, mice received up to two additional weekly boosts.
 
Cell Preparation. 
 
Single-cell suspensions of splenocytes, thy-
mocytes or liver cells were prepared by gently pressing the tissue
through a sterile 70-
 
 
 
m stainless steel mesh into RPMI 10
(RPMI 1640 supplemented with 10% FCS, 50 
 
 
 
M 2-ME, non-
essential amino acids, 100 U/ml penicillin, and 100 U/ml strep-
tomycin). To isolate mononuclear cells from the liver, cell sus-
pensions from liver tissue were further washed once with RPMI
10, resuspended in an isotonic 33% Percoll solution (Sigma-
Aldrich) containing 100 U/ml of heparin, and were centrifuged
at 500 g for 15 min at room temperature. RBC were lysed with
RBC-lysing buffer (containing 150 mM NH
 
4
 
Cl and 10 mM
Tris-HCl) and washed twice in RPMI 10.
APCs were splenocytes from naive syngeneic mice injected s.c.
with 10 
 
 
 
g Flt3 ligand (Immunex) daily for nine consecutive
days. Splenocytes were irradiated (3,000 rad), washed, and resus-
pended in RPMI 10. APCs were enriched by incubating spleno-
cytes in plastic culture dishes for 2 h at 37
 
 
 
C. The adherent cells
were pulsed with ganglioside antigen (1 
 
 
 
g/ml 0.1% DMSO;
Matreya) or with control vehicle (0.1% DMSO). After overnight
incubation at 37
 
 
 
C, the nonadherent cells were collected,
washed, and used as APCs. Approximately 65% of CD11c
 
 
 
MHC class II
 
 
 
–enriched APCs from Flt3 ligand-treated mice
were found to be CD1d
 
 
 
 (unpublished data).
 
Antibody Blocking Experiments. 
 
mAb used in this work were
purchased from BD Biosciences unless otherwise noted. Before
loading with ganglioside, APCs were incubated with 10 
 
 
 
g/ml
anti–mouse-CD1d mAb (clone 20H2; American Type Culture
Collection), anti-K
 
b
 
/D
 
b
 
 (clone 28–8-6), anti–mouse I-A
 
b
 
 mAb
(clone KH74; American Type Culture Collection) mAb, or a
negative control Ter-119 mAb (21) against mouse erythroid cells
for 30 min at 4
 
 
 
C, and washed with RPMI 10 twice.
 
ELISPOT Assay. 
 
HA-Multiscreen plates (Millipore) were
coated with 10 
 
 
 
g/ml rat anti–mouse IL-4 (clone 11B11) or
IFN-
 
 
 
 (clone R4–6A2) mAb and blocked with RPMI 10 for 1 h
at 37
 
 
 
C. Splenocytes or T cell subsets from immunized mice
were plated in triplicate wells at 1–2 
 
 
 
 10
 
5
 
 in 100 
 
 
 
l. Effector
cells were stimulated with 1–2 
 
 
 
 10
 
4
 
 irradiated APCs in 100 
 
 
 
l
pulsed with 1 
 
 
 
g/ml ganglioside (0.1% DMSO) or with control
vehicle (0.1% DMSO). Control wells contained effector cells
alone, APCs alone, or medium alone. After incubation for 20 h at
37
 
 
 
C, plates were washed with PBS/0.05% Tween 20, followed
by incubation with 2 
 
 
 
g/ml biotinylated rat anti–mouse IL-4
(clone BVD6–24G2) or IFN-
 
 
 
 (clone XMG1.2) mAb for 2 h at
37
 
 
 
C. Plates were washed, and reacted with avidin–peroxidase
complex (Vectastain Elite Kit; Vector Laboratories) for 1 h at
room temperature. After washing, plates were developed with
3-amino-9-ethyl-carbazole substrate in H
 
2
 
O
 
2
 
 at room tempera-
ture for 4 min, and the reaction was stopped by washing plates
under running water. After the plates were dry, spots were counted
by using a stereomicroscope at a 40-fold magnification and an au-
tomated ELISPOT reader system (Carl Zeiss MicroImaging, Inc.)
with KS ELISPOT 4.0 software.
 
Flow Immunocytometric Analysis. 
 
mAbs against human CD1a-d
(provided by Dr. S. Porcelli, Albert Einstein College of Medi-
cine, Bronx, NY) were biotinylated for use in the flow cytomet-
ric analysis. Anti–mouse CD3 (FITC-conjugated, clone 17A2),
NK1.1 (PE-conjugated, clone PK136), CD4 (CyChrome–conju-
gated, clone RM4–5), CD8 (Cy-chrome–conjugated, clone 53–6.7),
IL-4 (allophycocyanin-conjugated, clone 11B11), IL-5 (allophy-
cocyanin-conjugated, clone TRFK5), IL-10 (allophycocyanin-
conjugated, clone JES5–16E3), IL-12 (allophycocyanin-conju-
gated, clone C15.6), IFN-
 
 
 
 (allophycocyanin-conjugated, clone
XMG1.2), and Tri-Color (TC)–conjugated streptavidin (Caltag
Laboratories) were used for staining.
For surface staining, 10
 
6
 
 cells were incubated with FITC- or
PE-conjugated mAb, or with biotin-conjugated mAb followed
by incubating with TC-conjugated streptavidin. Isotype-matched
mAb were used as negative controls. All incubations were for 20
min at 4
 
 
 
C, after which the cells were washed with FACS
 
®
 
 buffer
(containing 0.5% BSA and 0.05% sodium azide in PBS).
For intracellular cytokine staining, splenocytes were incubated
with APCs pulsed with 1 
 
 
 
g/ml GD3 or with control vehicle for
1 h at 37
 
 
 
C. 10 
 
 
 
g/ml Brefeldin A (Sigma-Aldrich) was added
and incubation was continued overnight at 37
 
 
 
C. 10
 
6
 
 cells were
surface-stained with fluorescence-conjugated anti-CD3 and
NK1.1 mAbs, fixed, and permeabilized by incubating with Cyto-
fix/Cytoperm solution (BD Biosciences), and incubated with al-
lophycocyanin-conjugated mAb against cytokine in 10
 
 
 
 Perm/
Wash Buffer (BD Biosciences). All incubations were performed
for 20 min at 4
 
 
 
C, after which the cells were washed with 1
 
 
 
Perm/Wash Buffer.
Acquisition was performed on a FACSCaliber™ (Becton
Dickinson), using forward- and side-scatter characteristics to
exclude dead cells. Data were analyzed using CELLQuest™
(Becton Dickinson).
For flow cytometry cell sorting, splenocytes pooled from six to
eight immunized mice were stained with fluorescence-conju-
gated anti–mouse CD3, NK1.1, CD4, and/or CD8 mAbs, and
subjected to cell sorting by MoFlow cell sorter. Splenocyte sub-
populations were sorted by surface expression of CD3, NK1.1,T
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CD4 and CD8: T cells (CD3
 
 
 
 NK1.1
 
 
 
), NKT cells (CD3
 
 
 
NK1.1
 
 
 
), CD4 NKT cells (CD4
 
 
 
 CD8
 
 
 
 CD3
 
 
 
 NK1.1
 
 
 
), CD8
NKT cells (CD4
 
 
 
 CD8
 
 
 
 CD3
 
 
 
 NK1.1
 
 
 
), DN NKT cells
(CD4
 
 
 
 CD8
 
 
 
 CD3
 
 
 
 NK1.1
 
 
 
), and NK cells (CD3
 
 
 
 NK1.1
 
 
 
).
 
Tetrameric Mouse CD1d–GD3 Complexes. 
 
Tetrameric mouse
CD1d–
 
 
 
2m complexes were produced using a baculovirus ex-
pression system as described previously (22). GD3 (Matreya) was
sonicated in 500 
 
 
 
M hexadecyltrimethylammonium bromide
(Sigma-Aldrich) and incubated with biotinylated CD1d mono-
mer overnight at a 3:1 molar ratio (GD3/CD1d). To prepare un-
loaded tetramers, 500 
 
 
 
m hexadecyltrimethylammonium bro-
mide alone was incubated with biotinylated CD1d monomer
overnight. To form tetramers, TC-conjugated streptavidin was
added at a 4:1 molar ratio (CD1d/streptavidin).
GD3 loading was confirmed by ELISA. Microtiter wells
(Maxisorb; Nunc) were coated with tetramers (350 ng CD1d/
well). Negative control wells were coated with unloaded tetra-
mers or GD3 alone (GD3 in aqueous solution binds only mini-
mally to the wells). After washing, the wells were blocked with
5% nonfat milk and probed with R24 (mouse IgG3 specific for
the carbohydrate portion of GD3) at 5–10 
 
 
 
g/ml. Bound R24
was detected with an alkaline phosphatase–conjugated rabbit
anti–mouse IgG3 second antibody. GD3 loading was assumed if
the tetramer wells showed an OD
 
405
 
 
 
 
 
10-fold higher than the
control wells.
For 
 
 
 
GalCer depletion experiments, 10
 
7
 
 splenocytes were in-
cubated with PE-conjugated 
 
 
 
GalCer-loaded mouse CD1d tet-
ramer (22) or unloaded CD1d tetramer for 30 min at room tem-
perature, washed twice with MACS buffer (0.5% BSA, 2 mM
EDTA in PBS), and incubated with anti-PE microbeads (Mil-
tenyi Biotec) for 15 min at 6–12
 
 
 
C. After washing twice with
MACS buffer, the cells were suspended in 500 
 
 
 
l MACS buffer
and applied to a prewetted MS
 
 /RS  separation column (Mil-
tenyi Biotec) in the magnetic field. The  GalCer-negative cells
were collected in the run-through.
Oligonucleotide Database.  GeneChip® analysis was performed
on SK-MEL-28 cell line (for the complete expression database,
see www.mskcc.org/genomic/ccsmsp; reference 23). In brief,
cryopreserved tumor sections were homogenized under liquid ni-
trogen by mortar and pestle. Total RNA was extracted in TRIzol
reagent and purified using the RNeasy kit (QIAGEN). RNA
quality was assessed on ethidium bromide agarose gel electro-
phoresis. cDNA was synthesized in the presence of oligo(dT)24-
T7 from Genset Corp. cRNA was prepared using biotinylated
UTP and CTP and hybridized to HG_U95A oligonucleotide ar-
rays (Affymetrix Inc.). Fluorescence was measured by laser confo-
cal scanner (Agilent Technologies) and converted to signal inten-
sity by Affymetrix Microarray Suite v5.0 software. Expression
values across each chip were normalized to the 96th percentile of
2,500. CD1a-d signal intensity was compared between SK-MEL-
28 and a set of 9 independent melanoma tumors and 19 mela-
noma cell lines.
Online Supplemental Material. SK-MEL-28 melanoma cells
were analyzed for expression of human CD1a, CD1b, CD1c, or
CD1d using FACS® analysis. MOLT-4 cells (CD1 ) were used as
positive control.
Results
Immunization Against GD3 Induces Lymphocytes That Rec-
ognize GD3.  Immunization of mice with human mela-
noma SK-MEL-28 cells (GD3 , GM2 ) expanded a popu-
lation of splenocytes that produced IL-4 in response to
GD3-loaded APCs but did not produce detectable IFN- 
after two immunizations (Fig. 1 a). These GD3-reactive
splenocytes were not detectable in the spleens of unimmu-
nized mice, which demonstrated that immunization with
the GD3  melanoma was critical for this response. Reac-
tivity to GD3 was not due to a general, nonspecific reactiv-
ity because splenocytes from immunized mice did not rec-
ognize unloaded APCs or APCs loaded with GM2, a
ganglioside not expressed by SK-MEL-28. This indicates
Figure 1. Lymphocyte re-
sponses induced against GD3 in
immunized mice produce IL-4.
Mice were immunized with 2  
106 SK-MEL-28 cells mixed
with CFA on day 0, and boosted
with 2   106 SK-MEL-28 cells
mixed with IFA on day 7. Con-
trol mice (Freund’s adjuvant
only) were injected with CFA
on day 0 followed by IFA alone
on day 7. (a) Splenocytes were
collected on day 14 and stimu-
lated with irradiated syngeneic
APCs loaded with GD3, GM2,
or without ganglioside (None) as
indicated. IL-4 and IFN- 
production were detected by
ELISPOT assay. (b) In other sets
of mice, hepatic mononuclear
cells and thymocytes were
tested for IL-4 secretion. Data
represent mean   SEM of trip-
licate wells from four mice and
similar results were observed in
repeated experiments.T
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176 Cross-presentation of GD3 to NKTs
that these splenocytes from immunized mice have some
degree of specificity. To exclude the possibility that the
splenocyte response against GD3 was induced by lipid
components in Freund’s adjuvant, we tested splenocytes
from mice injected with Freund’s adjuvant only. Spleno-
cytes from these mice showed no significant reactivity to
unloaded or GD3-loaded APCs, indicating that the spleno-
cyte response to GD3 observed in SK-MEL-28–immu-
nized mice was not due to the Freund’s adjuvant. In im-
munized mice, GD3-reactive lymphocytes were also
detected in the liver but not in the thymus (Fig. 1 b).
We wished to confirm that it was GD3 and not another
molecule expressed by SK-MEL-28 that was responsible
for immunization. To do this, mice were immunized by
footpad injection with syngeneic APCs loaded with puri-
fied GD3; control mice were immunized with unloaded
APCs. GD3-reactive lymphocytes were detected in the
draining LN, such as popliteal and inguinal LN, (Fig. 2 a) as
well as in the spleen (Fig. 2 b) of mice immunized with
GD3-loaded APCs. GD3-reactive lymphocytes were not
detected in control mice injected with unloaded APCs, or
when splenocytes from immunized mice were tested
against unloaded APCs in the ELISPOT assay. These stud-
ies confirmed that the immunizing molecule was GD3.
GD3-reactive Lymphocytes Are CD3  NK1.1  NKT
Cells. Splenocytes from immunized mice were sorted
based on CD3, NK1.1, CD4, and CD8 expression. When
each splenocyte subpopulation was tested for reactivity
against GD3-loaded APCs or unloaded APCs, GD3 reac-
tivity was observed only among the NK1.1 , CD3  sub-
populations (Fig. 3). Two groups of GD3-reactive NKT
cells were detected: CD4 CD8  and CD4 CD8  (DN).
We did not detect CD8  NKT cells reactive to GD3.
There was no reactivity against GD3 among T cells
(CD3 , NK1.1  lymphocytes) or classical NK cells
(CD3 , NK1.1  lymphocytes).
Recognition of GD3 by NKT Cells Is CD1d Restricted.
Because NKT cells recognize  GalCer presented by
CD1d, we were interested to know if the GD3-reactive
NKT cells were restricted by CD1d. Splenocytes from im-
munized mice were mixed with GD3-loaded APCs that
had been preincubated with mAb against CD1d, MHC
class I (Kb/Db), MHC class II (I-Ab), or Ter-119, a negative
control mAb. The NKT cell response to GD3 was blocked
by anti-CD1d mAb, but not by mAb against MHC class I,
class II, or control mAb (Fig. 4). Control experiments (un-
published data) demonstrated that the anti-Kb/Db and anti–
I-Ab mAb efficiently blocked T cell responses against influ-
enza A/PR/8 virus–derived NP peptide (ASNENMETM)
and human TRP2-derived H10 peptide (NESFALPYWN-
FATGRNECDV), respectively, demonstrating that the in-
ability of these mAbs to block NKT cell responses to GD3
was not due to the lack of blocking capability.
Figure 2. GD3-loaded APCs induced GD3-reactive lymphocytes pro-
ducing IL-4. Mice were injected with 105 GD3-loaded APCs or un-
loaded APCs into the footpad, as indicated. Popliteal and inguinal LN (a)
or splenocytes (b) were collected on day 7 and tested for reactivity against
irradiated syngeneic APCs loaded with GD3 or unloaded APCs (as neg-
ative control) as indicated. IL-4 production was detected by ELISPOT
assay. Each point represents the mean of triplicate wells from an individ-
ual mouse; horizontal lines indicate mean values of five mice.
Figure 3. GD3-reactive cells are CD4 8  NKT cells and CD4 8 
NKTs. Mice were immunized with 2   106 SK-MEL-28 cells mixed
with CFA on day 0, and boosted with 2   106 SK-MEL-28 cells mixed
with IFA on day 7. Splenocytes pooled from six to eight immunized mice
were separated into subpopulations based on their surface expression of
NK1.1, CD3, CD4, and CD8. Total cells (unseparated splenocytes), total
NKT cells (CD3  NK1.1 ), total conventional T cells (CD3  NK1.1 ),
CD4  NKT cells (CD4  CD8  CD3  NK1.1 ), CD8  NKT cells
(CD4  CD8  CD3  NK1.1 ), DN NKT cells (CD4  CD8  CD3 
NK1.1 ), and classic NK cells (CD3  NK1.1 ) populations were stimu-
lated with irradiated syngeneic APCs in the presence (  columns, closed
squares) or absence (  columns, open squares) of GD3. IL-4 production
by each cell population was detected by ELISPOT assay. Horizontal lines
indicate mean values.T
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To confirm that GD3 recognition by NKT cells was
CD1d dependent, splenocytes from immunized mice were
stimulated with GD3-loaded APCs from CD1d knockout
(CD1d / ) or wild-type (CD1d / ) mice. As shown in
Fig. 5, GD3-loaded APCs derived from CD1 /  mice
were not able to present GD3 to GD3-reactive NKTs.
These results confirm that CD1d is required for presenta-
tion of GD3 to the NKTs.
Quantification of the NKT Cell Response to GD3 Using
GD3-loaded Mouse CD1d Tetramers.  We wished to con-
firm the NKT cell response against GD3 and quantitate it
using a technique other than ELISPOT. To do this, we
analyzed the NKT cell response against GD3 using GD3-
loaded mouse CD1d tetramers. CD3  NK1.1  tetramer 
cells were detected among the splenocytes of immunized
mice, but not among splenocytes of control mice injected
only with Freund’s adjuvant (Fig. 6 a, left and middle). As
an important control, splenocytes from immunized mice
stained with unloaded CD1d tetramers showed only back-
ground levels of tetramer staining, indicating the specific-
ity of the GD3-loaded CD1d tetramers (Fig. 6 a, right).
Overall, among the CD3  NK1.1  splenocytes in immu-
nized mice, a mean of 4.5% tetramer  NKT cells was
compared with a mean of 1.2% in unimmunized mice or
in immunized mice stained with unloaded CD1d tetra-
mers, (P   0.001; Fig. 6 b). These experiments confirmed
that immunization expanded CD1d-restricted NKT cells
recognizing GD3.
GD3-reactive NKT Cells Are a Subset of  GalCer-reactive
NKT Cells.  Most CD1d-restricted mouse NKT cells ex-
press an invariant TCR encoded by V 14 and J 18 seg-
ments and react with  GalCer. We wished to determine if
GD3-reactive NKT cells were a subset of  GalCer-reac-
tive NKTs. Splenocytes from SK-MEL-28–immunized
mice were stained with PE-conjugated  GalCer-loaded
CD1d tetramer and depleted using anti-PE magnetic beads.
Figure 4. GD3-reactive NKT cell response is blocked by anti-CD1d
mAb. Irradiated APCs were preincubated with PBS alone (none) or with
anti-CD1d (CD1d), anti–Kb/Db (Kb/Db), anti–I-Ab (I-Ab), or 10  g/ml
Ter119 (irrel.) mAb before being loaded with GD3. Splenocytes from
mice immunized with SK-MEL-28 and Freund’s adjuvant were used as
effector cells and IL-4 production by splenocytes was detected by
ELISPOT assay. Data represent mean   SEM of triplicate wells from four
mice and are indicative of replicate experiments.
Figure 6. Detection of GD3-reactive NKT cells using CD1d-GD3
tetramers. Splenocytes from mice immunized with SK-MEL-28 cells and
Freund’s adjuvant (immunized) or mice injected with Freund’s adjuvant
only (control) were analyzed by flow cytometry for binding to FITC-
conjugated anti-CD3 mAb, PE-conjugated anti-NK1.1 mAb and TC-
conjugated GD3-loaded mCD1d tetramers or unloaded mCD1d tetramers.
Gating was performed on CD3  cells. (a) Double immunofluorescence
staining of cell surface expression of NK1.1 (PE, abscissa) and tetramer
(TC, ordinate) from representative immunized and control mice. Spleno-
cytes from an immunized mouse were stained with unloaded tetramer
(right). Double-positive cells are indicated by the framed window. (b)
Percent tetramer  cells among total CD3  NK1.1  splenocytes from
immunized and control mice stained with GD3-loaded CD1d tetramers,
and immunized mice stained with unloaded tetramer. Each point repre-
sents a single mouse. The difference in the mean values (horizontal lines)
was highly significant (P   0.001, Kruskal-Wallis test).
Figure 5. CD1d expression by APCs is required for presentation of
GD3 to NKT cells. Splenocytes from mice immunized with SK-MEL-28
and Freund’s adjuvant were used as effector cells and IL-4 production by
splenocytes was detected by ELISPOT assay. APCs were isolated from
the spleen of mCD1d knockout mice (CD1 / ) or from wild-type mice
(CD1 / ) as indicated and loaded with GD3. Control wells received un-
loaded APCs. Each point represents the mean of triplicate wells from an
individual mouse; horizontal lines indicate mean values.T
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Depletion was highly efficient reducing the  GalCer-
CD1d tetramer  CD3  population from 2.58%   0.171
( SEM) after mock depletion (splenocytes stained with
PE-conjugated unloaded CD1d tetramer before depletion)
to 0.04%   0.002 ( SEM).  GalCer-depleted and mock-
depleted cells were stained with TC-conjugated GD3-
loaded mouse CD1d tetramers. Fig. 7 illustrates that, after
mock depletion, a mean of 0.21% of the CD3  cells were
positive for GD3-loaded CD1d tetramer staining compared
with a mean of 0.06% after depletion of  GalCer-reactive
cells (P   0.005, Kruskal-Wallis test). These experiments
show that GD3-loaded mouse CD1d tetramers bind to a
subpopulation of  GalCer-reactive NKT cells.
Cytokine Profile of NKT Cells Against GD3.  The ki-
netics of cytokine production by GD3-reactive NKT cells
was determined by intracellular cytokine FACS® analysis
after immunizing mice weekly for up to three immuniza-
tions. After a single immunization on day 0, we detected
production of IL-4, IL-10, and IFN- , which peaked on
day 7 and diminished to baseline by day 10 (IL-4 and IFN- )
or by day 17 (IL-10; Fig. 8 a). We did not detect IL-5 or
IL-12 production by GD3-reactive NKT cells. These re-
sults indicate that, after a single immunization, the NKT
cell response against GD3 is limited. In mice receiving
weekly immunizations (Fig. 8 b), IFN-  production by
NKT cells was not sustained beyond day 10, despite
booster immunizations on day 7 and day 14. This is consis-
tent with our previous observations (Fig. 1 a), in which lit-
tle IFN-  secretion was detected after two immunizations
and indicates that the IFN-  response in these cells is tran-
sient despite further immunizations. IL-4 production by
GD3-reactive NKT cells was detectable after the first im-
munization and peaked after the second immunization.
However, despite a third immunization on day 14, IL-4
production decreased, indicating that the NKT cell re-
sponse against GD3 could not be sustained. No IL-4 pro-
duction was detected if splenocytes were incubated with
unloaded APCs or if splenocytes from mice immunized
with adjuvant alone were used (unpublished data), con-
firming the specificity of the response.
GD3-reactive NKT cells also produced IL-10, which
was detected after a single immunization (Fig. 8 a). With
weekly immunizations, the number of IL-10–secreting
NKT cells expanded, reaching a peak on day 17, which
was 2 d after the third immunization. Without additional
immunizations, the number of IL-10–secreting NKT cells
reacting to GD3 diminished afterwards.
GD3 Is Cross-presented by Host CD1  APCs.  Because
GD3 is presented to NKT cells by CD1d, and the immu-
nizing cell was a human GD3  cell line, we considered it
likely that the GD3 was cross-presented by CD1d  mouse
Figure 7. Effects of  GalCer-reactive NKT cell depletion on GD3 re-
activity. Splenocytes from immunized mice were either depleted of
 GalCer-loaded CD1d tetramer-reactive cells and stained with TC-con-
jugated GD3-loaded CD1d tetramer ( ), or mock-depleted of  GalCer-
loaded CD1d tetramer-reactive cells and stained with TC-conjugated
GD3-loaded CD1d tetramer ( ) or with TC-conjugated unloaded
mouse CD1d tetramer ( ). Gating was performed on CD3  cells and
each point represents a single mouse. P   0.005, Kruskal-Wallis test.
Horizontal lines indicate mean values.
Figure 8. Cytokine production by GD3-reactive NKTs. Mice were
immunized with 2   106 SK-MEL-28 cells mixed with CFA on day 0
without further boost (a), or were immunized with 2   106 SK-MEL-28
cells mixed with CFA on day 0 and boosted with 2   106 SK-MEL-28
cells mixed with IFA on day 7 and day 14 (b). Splenocytes were collected
at the time points indicated. Intracellular production of IL-4 ( ), IL-5
( ), IL-10 ( ), IL-12 ( ) and IFN-  ( ) by NK1.1  CD3  cells was
measured gating on CD3  cells. Arrows indicate time of immunization.
Data represent mean   SEM from four mice, and similar results were ob-
served in repeated experiments.T
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APCs. However, it was formally possible that the GD3
could be presented by SK-MEL-28 if it expressed human
CD1 because there is evidence that human CD1 can
present glycolipid antigens to mouse NKT cells (24). To
test this, we probed SK-MEL-28 for human CD1a, CD1b,
CD1c, and CD1d expression using FACS® analysis. We
found that SK-MEL-28 cells did not express any isoforms
of human CD1 (Fig. S1 available at http://www.jem.org/
cgi/content/full/jem.20030446/DC1). Our previous ex-
periments indicated that some inflammatory cytokines (i.e.,
IFN- , IFN- , and TNF- ) could up-regulate CD1d ex-
pression on some of human melanoma cell lines, but treat-
ment of SK-MEL-28 with those cytokines did not result
in CD1 expression. Consistent with these observations,
cDNA array experiments with SK-MEL-28 demonstrated
that there was no expression of mRNA encoding any of
the human CD1 isoforms (unpublished data). Therefore,
on both the mRNA and protein levels, we are satisfied that
SK-MEL-28 does not express human CD1 and could not
have presented GD3 to mouse NKTs. As a result, we con-
clude that GD3 was cross-presented by CD1d  mouse
APCs.
Discussion
GD3 is a ganglioside abundantly expressed on human tu-
mors of neuroectodermal origin such as melanoma, sar-
coma, neuroblastoma, and small cell lung cancer cells. Be-
cause GD3 is not expressed, or expressed at low levels, on
normal human tissues, it has been an attractive target for
immunotherapy. Attempts to immunize animals (25) and
patients (26–28) against GD3 have focused exclusively on
antibody responses because gangliosides are T cell–inde-
pendent antigens and not recognized by classical MHC-
restricted T cells. There is evidence in humans that group 1
CD1 molecules (CD1a, CD1b, and CD1c) can present gly-
colipids, but aside from  GalCer, glycolipids presented by
group 2 CD1 molecules (i.e., CD1d) have not been identi-
fied. Although T cells have been described that can recog-
nize GM1 ganglioside presented by group 1 CD1 mole-
cules (18), natural ligands recognized by NKT cells have
not been described. In this paper, we demonstrate that
mice immunized with GD3  human melanoma developed
a CD1d-restricted NKT cell response against GD3 and that
the GD3 was cross-presented by mouse APCs. We also
show that a similar response could be generated by immu-
nizing mice with syngeneic APCs loaded with GD3, con-
firming that the response was to GD3 and not to other
molecules on human melanoma. Crowe et al. showed that
NKT cells from wild-type mice could prevent outgrowth
of the MCA sarcoma induced in NKT–deficient mice that
had been transplanted into NKT–deficient mice, but could
not prevent outgrowth when the sarcoma was transplanted
into CD1 /  mice (29). Although cross-presentation was
not demonstrated formally and a specific antigen recog-
nized by the NKT cells was not identified, these data are
consistent with our observations and support the notion
that antigens can be cross-presented to NKTs.
GD3-reactive NKT cells were found to be a subset of
 GalCer-reactive NKTs. Although we were not able to
carry out an exhaustive specificity analysis, the NKT cells
failed to recognize GM2, a structurally related ganglioside,
which suggests some degree of specificity. This is the first
example of NKT cells recognizing a natural ligand.
We were able to quantify the CD1d-restricted GD3-
reactive NKT cell response using both ELISPOT and mouse
CD1d tetramers loaded with GD3. Previous tetramer anal-
yses of NKT cells have largely focused on tetramers loaded
with  GalCer, which mark virtually all NKTs (10, 11, 22).
Our tetramer studies indicated that 0.29% of CD3  cells in
splenocytes of immunized mice ( 1:345 CD3  cells) were
tetramer-positive NKT cels. When considering total sple-
nocytes, this corresponded to a mean of 54.4   7.3 tet-
ramer-positive NKT cells per 105 splenocytes (1:1,828). By
ELISPOT analysis, the frequency of NKT cells that pro-
duced IL-4 in response to GD3 was  1:2,000 splenocytes,
which matches almost exactly the frequency measured by
tetramer. This validates these two assays and indicates that
there were no anergic NKT cells detected by tetramer
analysis. It is interesting to note that this is the same fre-
quency of glycolipid-reactive T cells observed in patients
with multiple sclerosis (18) and suggests that this frequency
of NKT cells could be a clinically relevant.
GD3-reactive NKT cells secreted IL-4, IL-10, and IFN- ,
but not IL-5, or IL-12. With further immunization, the
NKT cell response to GD3 became polarized toward a
TH2-like response with subsequent extinguishing of the
IFN-  response. The IL-4 response peaked after two im-
munizations and began to wane despite additional booster
immunizations. GD3-reactive NKT cells also produced IL-
10, which peaked after three immunizations. From the ki-
netics of this response, we speculate that the IL-10 response
may turn off the NKT cell response against GD3 despite
further immunizations.
The NKT cell response we observed against GD3 is typi-
cal of TH2-like cells, although the cells also produced some
IFN-  transiently. A similar cytokine profile of elevated IL-4
and/or IL-10 production and low level IFN-  production
has been observed in several models of NKT–mediated im-
mune protection from autoimmune diseases. In the model
of anterior chamber–associated immune deviation, IL-10–
producing NKT cells are required to generate regulatory T
cells that suppress delayed-type hypersensitivity, although
the antigen recognized by the NKT cells is unknown (30).
In another model (experimental autoimmune encephalo-
myelitis [EAE]), preimmunization of mice with an analogue
of  GalCer activated NKT cells secreting IL-4 that blocked
development of EAE (31). Although we do not have any
additional information about the precise immunological ef-
fects of the GD3-reactive NKT cells observed in this work,
we have noted that IgG antibodies against GD3 are easily
induced in the mouse (32) and one speculation is that NKT
cells could provide T cell help for IgG class switching dur-
ing the humoral response to GD3. There is evidence that
NKT cells can provide T cell help to B cells resulting in en-
hanced immunoglobulin secretion (33).T
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In summary, we have shown that mouse TH2-like NKT
cells can recognize GD3 in a CD1d-restricted manner and
that the GD3 is cross-presented by mouse APCs. The re-
sponse seems to be self-limited, possibly due to IL-10 pro-
duction that correlated with extinguishing of the IL-4 re-
sponse. Extrapolating to the human system, we speculate
that in patients with GD3  tumors, the GD3 could be
cross-presented and may induce an NKT cell response. We
are currently studying whether NKT cells against GD3 can
be detected in melanoma patients immunized against GD3.
We thank Dr. G. Ritter for helpful suggestions, Dr. S. Porcelli for
mAbs against human CD1 and for valuable discussions, and S. Lu
for technical assistance.
This paper was supported with funds from the National Cancer
Institute under grants K24 CA81293 (to P.B. Chapman) and RO1
CA2511 (to M. Kronenberg), and the Swim Across America
Foundation.
Submitted: 21 March 2003
Revised: 13 May 2003
Accepted: 14 May 2003
References
1. Porcelli, S.A., and R.L. Modlin. 1999. The CD1 System:
Antigen-presenting molecules for T cell recognition of lipids
and glycolipids. Annu. Rev. Immunol. 17:297–329.
2. Moody, D.B., B.B. Reinhold, M.R. Guy, E.M. Beckman,
D.E. Frederique, S.T. Furlong, S. Ye, V.N. Reinhold, P.A.
Sieling, R.L. Modlin, G.S. Besra, and S.A. Porcelli. 1997.
Structural requirements for glycolipid antigen recognition by
CD1b-restricted T cells. Science. 278:283–286.
3. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K.
Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, H.
Koseki, and M. Taniguchi. 1997. CD1d-restricted and
TCR-mediated activation of v 14 NKT cells by glycosyl-
ceramides. Science. 278:1626–1629.
4. Shamshiev, A., A. Donda, T.I. Prigozy, L. Mori, V. Chig-
orno, C.A. Benedict, L. Kappos, S. Sonnino, M. Kronen-
berg, and G. De Libero. 2000. The    T cell response to
self-glycolipids shows a novel mechanism of CD1b loading
and a requirement for complex oligosaccharides. Immunity.
13:255–264.
5. Porcelli, S.A., B.W. Segelke, M. Sugita, I.A. Wilson, and
M.B. Brenner. 1998. The CD1 family of lipid antigen-pre-
senting molecules. Immunol. Today. 19:362–368.
6. Zeng, Z., A.R. Castano, B.W. Segelke, E.A. Stura, P.A.
Peterson, and I.A. Wilson. 1997. Crystal structure of mouse
CD1: an MHC-like fold with a large hydrophobic binding
groove. Science. 277:339–345.
7. Bendelac, A., M.N. Rivera, S.H. Park, and J.H. Roark.
1997. Mouse CD1-specific NK1 T cells: development, spec-
ificity, and function. Annu. Rev. Immunol. 15:535–562.
8. Lantz, O., and A. Bendelac. 1994. An invariant T cell recep-
tor   chain is used by a unique subset of major histocompati-
bility complex class I–specific CD4  and CD4-8–T cells in
mice and humans. J. Exp. Med. 180:1097–1106.
9. Bendelac, A., O. Lantz, M.E. Quimby, J.W. Yewdell, J.R.
Bennink, and R.R. Brutkiewicz. 1995. CD1 recognition by
mouse NK1  T lymphocytes. Science. 268:863–865.
10. Benlagha, K., A. Weiss, A. Beavis, L. Teyton, and A. Ben-
delac. 2000. In vivo identification of glycolipid antigen-spe-
cific T cells using fluorescent CD1d tetramers. J. Exp. Med.
191:1895–1903.
11. Burdin, N., L. Brossay, Y. Koezuka, S.T. Smiley, M.J.
Grusby, M. Gui, M. Taniguchi, K. Hayakawa, and M. Kro-
nenberg. 1998. Selective ability of mouse CD1 to present
glycolipids: alpha-galactosylceramide specifically stimulates V
alpha 14  NK T lymphocytes. J. Immunol. 161:3271–3281.
12. Pukel, C.S., K.O. Lloyd, L.R. Travassos, W.G. Dippold,
H.F. Oettgen, and L.J. Old. 1982. GD3, a prominent ganglio-
side of human melanoma. Detection and characterization by
mouse monoclonal antibody. J. Exp. Med. 155:1133–1147.
13. Kusano, A., S. Ohta, K. Shitara, and N. Hanai. 1993. Immu-
nocytochemical study on internalization of anti-carbohydrate
monoclonal antibodies. Anticancer Research. 13:2207–2212.
14. Chapman, P.B., M. Lonberg, and A.N. Houghton. 1990.
Light chain variants of an IgG3 anti-GD3 monoclonal anti-
body and the relationship between avidity, effector functions,
tumor targeting, and antitumor activity. Cancer Res. 50:1503–
1509.
15. Vadhan-Raj, S., C. Cordon-Cardo, E.A. Carswell, D. Mint-
zer, L. Dantis, C. Duteau, M.A. Templeton, H.F. Oettgen,
L.J. Old, and A.N. Houghton. 1988. Phase I trial of a mouse
monoclonal antibody against GD3 ganglioside in patients
with melanoma: induction of inflammatory responses at tu-
mor sites. J. Clin. Oncol. 6:1636–1648.
16. Nasi, M., M. Meyers, P. Livingston, A. Houghton, and P.
Chapman. 1997. Anti-melanoma effects of R24, a mono-
clonal antibody against GD3. Vaccine Research. 7:S155–S162.
17. Ladisch, S., H. Becker, and L. Ulsh. 1992. Immunosuppres-
sion by human gangliosides: I. Relationship of carbohydrate
structure to the inhibition of T cell responses. Biochim. Bio-
phys. Acta. 1125:180–188.
18. Shamshiev, A., A. Donda, I. Carena, L. Mori, L. Kappos, and
G. De Libero. 1999. Self glycolipids as T-cell autoantigens.
Eur. J. Immunol. 29:1667–1675.
19. Tallquist, M.D., T.J. Yun, and L.R. Pease. 1996. A single T
cell receptor recognizes structurally distinct MHC–peptide
complexes with high specificity. J. Exp. Med. 184:1017–
1026.
20. Ruan, S., and K.O. Lloyd. 1992. Glycosylation pathways in
the biosynthesis of gangliosides in melanoma and neuroblas-
toma cells: relative glycosyltransferase levels determine gan-
glioside patterns. Cancer Res. 52:5725–5731.
21. Kina, T., K. Ikuta, E. Takayama, K. Wada, A.S. Majumdar,
I.L. Weissman, and Y. Katsura. 2000. The monoclonal anti-
body TER-119 recognizes a molecule associated with glyco-
phorin A and specifically marks the late stages of murine
erythroid lineage. Br. J. Haematol. 109:280–287.
22. Matsuda, J.L., O.V. Naidenko, L. Gapin, T. Nakayama, M.
Taniguchi, C.R. Wang, Y. Koezuka, and M. Kronenberg.
2000. Tracking the response of natural killer T cells to a gly-
colipid antigen using CD1d tetramers. J. Exp. Med. 192:741–
754.
23. Segal, N.H., P. Pavlidis, W.S. Noble, C.R. Antonescu, A.
Viale, U.V. Wesley, K. Busam, H. Gallardo, D. DeSantis,
M.F. Brennan, et al. 2003. Classification of clear-cell sarcoma
as a subtype of melanoma by genomic profiling. J. Clin. On-
col. 21:1775–1781.
24. Brossay, L., M. Chioda, N. Burdin, Y. Koezuka, G. Casorati,
P. Dellabona, and M. Kronenberg. 1998. CD1d-mediated
recognition of an  -galactosylceramide by natural killer T
cells is highly conserved through mammalian evolution. J.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
181 Wu et al.
Exp. Med. 188:1521–1528.
25. Chapman, P.B., and A.N. Houghton. 1991. Induction of
IgG antibodies against GD3 in rabbits by an anti-idiotypic
monoclonal antibody. J. Clin. Invest. 88:186–192.
26. Ritter, G., E. Boosfeld, R. Adluri, M. Calves, H.F. Oettgen,
L.J. Old, and P.O. Livingston. 1991. Antibody response to
immunization with ganglioside GD3 and GD3 congeners
(lactones, amide and gangliosidol) in patients with malignant
melanoma. Int. J. Cancer. 48:379–385.
27. McCaffery, M., T.-J. Yao, L. Williams, P.O. Livingston,
A.N. Houghton, and P.B. Chapman. 1996. Enhanced im-
munogenicity of BEC2 anti-idiotypic monoclonal antibody
that mimics GD3 ganglioside when combined with adjuvant.
Clin. Cancer Res. 2:679–686.
28. Ragupathi, G., M. Meyers, S. Adluri, L. Howard, L. Mus-
selli, and P.O. Livingston. 2000. Induction of antibodies
against GD3 ganglioside in melanoma patients by vaccination
with GD3-lactone-KLH conjugate plus immunological adju-
vant QS-21. Int. J. Cancer. 85:659–666.
29. Crowe, N.Y., M.J. Smyth, and D.I. Godfrey. 2002. A critical
role for natural killer T cells in immunosurveillance of meth-
ylcholanthrene-induced sarcomas. J. Exp. Med. 196:119–127.
30. Sonoda, K.H., D.E. Faunce, M. Taniguchi, M. Exley, S.
Balk, and J. Stein-Streilein. 2001. NK T cell-derived IL-10 is
essential for the differentiation of antigen-specific T regula-
tory cells in systemic tolerance. J. Immunol. 166:42–50.
31. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A syn-
thetic glycolipid prevents autoimmune encephalomyelitis by
inducing TH2 bias of natural killer T cells. Nature. 413:531–
534.
32. Yan, X., S.V. Evans, M.J. Kaminski, S.D. Gillies, R.A. Reis-
feld, A.N. Houghton, and P.B. Chapman. 1996. Character-
ization of an Ig VH idiotope that results in specific ho-
mophilic binding and increased avidity for antigen. J.
Immunol. 157:1582–1588.
33. Galli, G., S. Nuti, S. Tavarini, L. Galli-Stampino, C. De Lalla,
G. Casorati, P. Dellabona, and S. Abrignani. 2003. CD1d-
restricted help to B cells by human invariant natural killer T
lymphocytes. J. Exp. Med. 197:1051–1057.